Skip to main content
Livermore
Livermore
ZHEN

UBS Group AG

SEC CIK
0001610520
Latest filing
Aug 13, 2026

RAPT holding history

RAPT Therapeutics, Inc. in every 13F filed by UBS Group AG, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

RAPT overviewAll 13F holders of RAPTFull Q2 2026 holdings

Shares (Q1 2026)
0
Sold out in Q1 2026
Value
$0
% of portfolio
0.0%
Quarters held
20
Since Q1 2021
Holdings of RAPT by UBS Group AG, by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q1 20260$00.0%−66,225−100.0%Sold outHolders
Q4 202566,225$2.24M<0.1%+37,417+129.9%AddedHolders
Q3 202528,808$743.0K<0.1%+25,116+680.3%AddedHolders
Q2 20253,692$29.5K<0.1%−157,144−97.7%ReducedHolders
Q1 2025160,836$196.2K<0.1%+11,167+7.5%AddedHolders
Q4 2024149,669$236.5K<0.1%+120,823+418.9%AddedHolders
Q3 202428,846$58.0K<0.1%+258+0.9%AddedHolders
Q2 202428,588$87.2K<0.1%−26,979−48.6%ReducedHolders
Q1 202455,567$499.0K<0.1%−34,443−38.3%ReducedHolders
Q4 202390,010$2.24M<0.1%+55,706+162.4%AddedHolders
Q3 202334,304$570.1K<0.1%−13,096−27.6%ReducedHolders
Q2 202347,400$886.4K<0.1%−1,405−2.9%ReducedHolders
Q1 202348,805$895.6K<0.1%−50,939−51.1%ReducedHolders
Q4 202299,744$1.97M<0.1%+88,229+766.2%AddedHolders
Q3 202211,515$277.0K<0.1%+8,824+327.9%AddedHolders
Q2 20222,691$49.0K<0.1%−42,271−94.0%ReducedHolders
Q1 202244,962$989.0K<0.1%−33,151−42.4%ReducedHolders
Q4 202178,113$2.87M<0.1%+71,883+1,153.8%AddedHolders
Q3 20216,230$193.0K<0.1%+52+0.8%AddedHolders
Q2 20216,178$196.0K<0.1%−2,798−31.2%ReducedHolders
Q1 20218,976$199.0K<0.1%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.